Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis

Critical Care Medicine

Volumn 39, Issue 1, 2011, Pages 19-25

  Vilay, A Mary ^a   Grio, Maricor ^b   Depestel, Daryl D ^c,d   Sowinski, Kevin M ^e,f   Gao, Lihong ^g   Heung, Michael ^d,h   Salama, Noha N ^c,i,j   Mueller, Bruce A ^c,d  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b ARNOLD PALMER HOSPITAL FOR CHILDREN   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e PURDUE UNIVERSITY   (United States)

^f INDIANA UNIVERSITY   (United States)

^g CUBIST PHARMACEUTICALS INC   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ ST LOUIS COLLEGE OF PHARMACY   (United States)

^j CAIRO UNIVERSITY   (Egypt)

more..

Author keywords

critical illness; daptomycin; intensive care units; kidney failure; pharmacokinetics; renal dialysis

Indexed keywords

CB 183253; DAPTOMYCIN; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMODIALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; FEMALE; GRAM POSITIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEADY STATE;

EID: 78651255371     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181fa36fb     Document Type: Article

References (35)

1. Fluit AC, Verhoef J, Schmitz FJ, et al: Frequency of isolation and antimicrobial resistance of Gram-negative and Gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY antimicrobial surveillance program 1997-1998. Eur J Clin Microbiol Infect Dis 2001;20:617-625
2. Streit JM, Jones RN, Sader HS, et al: Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: Report from the SENTRY antimicrobial surveillance program (North America, 2001). Int J Antimicrob Agents 2004;24:111-118
3. Bayram A, Balci I: Patterns of antimicrobial resistance in a surgical intensive care unit of a university hospital in Turkey. BMC Infect Dis 2006;6:155
4. Zhanel GG, DeCorby M, Laing N, et al: Antimicrobial- resistant pathogens in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother 2008;52:1430-1437
5. Vincent JL, Rello J, Marshall J, et al: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-2329
6. Brivet FG, Kleinknecht DJ, Loirat P, et al: Acute renal failure in intensive care units- Causes, outcome, and prognostic factors of hospital mortality;a prospective, multicenter study French study group on acute renal failure. Crit Care Med 1996;24:192-198
7. Mehta RL, Pascual MT, Soroko S, et al: Spectrum of acute renal failure in the intensive care unit: The PICARD experience. Kidney Int 2004;66:1613-1621
8. Uchino S, Kellum JA, Bellomo R, et al: Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005;294:813-818
9. Uchino S, Bellomo R, Morimatsu H, et al: Continuous renal replacement therapy: A worldwide practice survey: The beginning and ending supportive therapy for the kidney (BEST kidney) investigators. Intensive Care Med 2007;33:1563-1570
10. Ostermann M, Chang RW: Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007;35:1837-1843;quiz 1852
11. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273:117-123
12. de Mendonca A, Vincent JL, Suter PM, et al: Acute renal failure in the ICU: Risk factors and outcome evaluated by the SOFA score. Intensive Care Med 2000;26:915-921
13. Woodworth JR, Nyhart EH Jr, Brier GL, et al: Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992;36:318-325
14. Dvorchik BH, Brazier D, DeBruin MF, et al: Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47:1318-1323
15. Dvorchik B, Damphousse D: Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J Clin Pharmacol 2004;44:612-620
16. Dvorchik B, Arbeit RD, Chung J, et al: Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004;48: 2799-2807
17. Benvenuto M, Benziger DP, Yankelev S, et al: Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245-3249
18. Chakraborty A, Roy S, Loeffler J, et al: Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother 2009;64:151-158
19. Liang SH, Sheng WH, Huang YT, et al: Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population. Chemotherapy 2009;55: 91-96
20. Salama NN, Segal JH, Churchwell MD, et al: Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol 2009;4:1190-1194
21. Churchwell MD, Pasko DA, Mueller BA: Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006;24:548-554
22. Dvorchik B: Moderate liver impairment has no influence on daptomycin pharmacokinetics. J Clin Pharmacol 2004;44:715-722
23. Dvorchik BH, Damphousse D: The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005;45: 48-56
24. Mohr JF 3rd, Ostrosky-Zeichner L, Wainright DJ, et al: Pharmacokinetic evaluation of single- dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother 2008;52:1891-1893
25. VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, et al: Intensity of renal support in critically ill patients with acute kidney injury N Engl J Med 2008 359 7-20.
26. Lee CS, Marbury TC: Drug therapy in patients undergoing haemodialysis: Clinical pharmacokinetic considerations. Clin Pharmacokinet 1984;9:42-66
27. Choi G, Gomersall CD, Tian Q, et al: Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009;37:2268-2282
28. Leypoldt JK, Kamerath CD, Gilson JF, et al: Dialyzer clearances and mass transfer-area coefficients for small solutes at low dialysate flow rates. ASAIO J 2006;52:404-409
29. Khadzhynov D, Slowinski T, Lieker I, et al: Pharmacokinetics of daptomycin under CVVHD in critically ill patients with renal failure. J Am Soc Nephrol 2009;20:549A (abstract SA-PO2348)
30. Stratton CW, Liu C, Weeks LS: Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, cipro- floxacin, and vancomycin against Staphylococci as determined by kill-kinetic studies. Antimicrob Agents Chemother 1987;31: 1210-1215
31. Flandrois JP, Fardel G, Carret G: Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus. Antimicrob Agents Chemother 1988;32: 454-457
32. Van der Auwera P: Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin. Antimicrob Agents Chemother 1989;33:1783-1790
33. Vance-Bryan K, Larson TA, Rotschafer JC, et al: Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1992;36: 2334-2337
34. Rose WE, Rybak MJ, Kaatz GW: Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: An in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007;60:334-340
35. Bhavnani SM, Rubino CM, Ambrose PG, et al: Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: Data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010;50:1568-1574